The Claim
BPC 157 reduces corneal neovascularization and preserves corneal transparency in rat models of corneal injury by counteracting pathological angiogenesis without inducing vascular growth.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In rats with corneal injury, BPC 157 reduces abnormal blood vessel growth in the cornea and maintains clear vision without triggering new blood vessel formation.
See the scientific wording
BPC 157, a stable gastric pentadecapeptide, counteracts pathological angiogenesis and reduces corneal neovascularization in rat models of corneal injury, preserving corneal transparency without inducing vascular growth, suggesting a unique regulatory role in angiogenic balance distinct from classical pro-angiogenic agents.
BPC 157 stabilizes the balance of signals that control blood vessel growth in the eye. It reduces excessive signals that cause abnormal blood vessels to form after injury, while keeping the signals needed for normal healing active. This prevents cloudiness in the cornea by stopping unwanted blood vessels from growing into clear tissue.
What the research says
1 studyIn rats with injured eyes, BPC 157 helped the cornea heal without letting weird blood vessels grow, keeping the eye clear—unlike other treatments that might cause those unwanted vessels.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.